Free Trial
NASDAQ:HEPA

Hepion Pharmaceuticals Q3 2023 Earnings Report

Hepion Pharmaceuticals logo
$0.06 -0.01 (-7.69%)
As of 03:53 PM Eastern

Hepion Pharmaceuticals EPS Results

Actual EPS
-$137.00
Consensus EPS
-$134.00
Beat/Miss
Missed by -$3.00
One Year Ago EPS
N/A

Hepion Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hepion Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 20, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Hepion Pharmaceuticals' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Earnings Documents

Hepion Pharmaceuticals Earnings Headlines

Dollar Collapse Warning: Protect Your Wealth NOW
Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Americans are shifting savings out of traditional accounts to protect what they’ve earned. If you’re concerned about inflation, rising debt, or a falling dollar, this free Wealth Protection Kit includes three timely reports to help you prepare for what’s coming next.
See More Hepion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA), a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

View Hepion Pharmaceuticals Profile

More Earnings Resources from MarketBeat